IL-12 GEMys Trial for Relapsed Solid Tumors Initiated by NCI
A clinical trial is underway to evaluate genetically engineered myeloid cells producing IL-12 in patients with relapsed or refractory solid tumors.
Asset / Drug
Drug and asset intelligence for Relapsed Solid with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Cell Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.